The chromosomal inversion (16)(p13q22), which is associated with the M4-eosinophilia subtype of human acute myeloid leukemia, causes the fusion of two distinct genes 
Introduction
Chromosomal inversion (16)(p13q22) is found to be consistently associated with the M4-eosinophilia (Eo) subtype of human acute myeloid leukemia (AML). This type of chromosomal abnormality involves both the PEBP2␤/CBF␤ and MYH11 genes and generates reciprocal fusion genes between them. [1] [2] [3] One species of chimeric transcript, which results from an in-frame gene fusion between these genes, encodes the PEBP2␤/CBF␤-SMMHC polypeptide and is cytogenetically important in leukemogenesis. The amino-terminal portion of the chimeric protein contains most of the PEBP2␤/CBF␤ protein, whereas the carboxy-terminal half consists of part of the rod domain of the smooth muscle myosin heavy chain (SMMHC) molecule. The non-rearranged PEBP2␤/CBF␤ gene encodes the non-DNA binding subunit of the heterodimeric transcription factor, PEBP2/CBF. 4, 5 The DNA binding activity of PEBP2/CBF, on the other hand, is derived from polypeptides encoded by the three mammalian, runt gene homologs including AML1. [6] [7] [8] The AML1 gene is involved in the pathogenesis of several subtypes of AML. [9] [10] [11] For instance, in the chromosomal translocation t(8;21)(q22;q22) associated with the M2 subtype of AML, the portion of the AML1 sequence encoding the DNA-binding Runt domain is fused to another gene, MTG8/ETO. [12] [13] [14] Both types of chimeric polypeptides, namely PEBP2␤/CBF␤-SMMHC and AML1-MTG8/ETO, are known to interfere with the physiological function of the PEBP2/CBF transcription factor. In most reports, PEBP2␤/CBF␤-SMMHC inhibited PEBP2/CBF site dependent transcriptional activation as measured by reporter assays. [15] [16] [17] Furthermore, a dominant interfering effect of PEBP2␤/CBF␤-SMMHC on PEBP2/CBF function has been demonstrated in a remarkable fashion by a PEBP2␤/CBF␤-MYH11 knocking-in strategy. 18 Murine embryos that were heterozygous for the chimeric allele, eg PEBP2␤/CBF␤-MYH11/+, revealed phenotypes similar to those of PEBP2␤/CBF␤ (−/−) or AML1 (−/−) embryos. Thus, abolition of PEBP2/CBF function by PEBP2␤/CBF␤-SMMHC is considered one of the molecular mechanism(s) leading to leukemogenesis.
Recently, sequestration of a DNA-binding, Runt homolog by PEBP2␤/CBF␤-SMMHC within the cytoplasm was proposed to be a mechanism for the dominant interfering effect of the chimeric protein. 17, 19 This notion was based on the observation that, while the Runt homolog by itself was located in the nucleus, the presence of PEBP2␤/CBF␤-SMMHC resulted in retention of the Runt homolog in the cytoplasm. The latter situation appears plausible, since PEBP2␤/CBF␤-SMMHC can still bind the Runt homologs. 15 It must be noted, though, that these results were obtained by transfecting the PEBP2␤/CBF␤-SMMHC expression plasmid into NIH3T3 fibroblasts and REF52 cells or Jurkat cells of the T cell lineage. 17, 19 Thus, we were interested to see if sequestration of Runt homologs by PEBP2␤/CBF␤-SMMHC could occur in the cytoplasm of leukemic cells carrying the inversion 16.
Materials and methods

Cells
Two leukemic cell lines and one clinical isolate were used in this study. The ME-1 and Kasumi-1 cell lines have been established from leukemic cells carrying inv(16)(p13q22) and t(8;21)(q22;q22), respectively. 20, 21 They were maintained in RPMI 1640 medium supplemented with 10% (vol/vol) fetal calf serum. Fresh peripheral white blood cells (WBC) were obtained from a 10-month-old Japanese boy who was diagnosed as suffering from the M4Eo subtype of AML (FAB classification). The number of WBC was 7 × 10 4 /l with 70% monoblasts. Chromosome analysis of the bone marrow cells showed 46XY, inv(16)(p13q22).
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RT-PCR analysis
The procedures for preparing total cytoplasmic RNA and for reverse transcription and PCR amplification have been described previously. 22 The C1 sense and M1 antisense primers to detect the PEBP2␤/CBF␤-MYH11 chimeric transcript were 5Ј-caggcaaggtatatttgaagg-3Ј and 5Ј-ctcctcttctcctc attctgctc-3Ј, respectively.
1,2 Amplified products were run on a 2% (wt/vol) agarose gel and stained with ethidium bromide.
Subcellular fractionation
The procedure to prepare cytosolic, membrane and nuclear fractions of cells was described previously. 23 Briefly, the cells were suspended in a buffer containing 10 mM Hepes-KOH, pH 7.6, 10 mM KCl, 1.5 mM MgCl 2 , 0.5 mM dithiothreitol, 1 mM EDTA, 1 mM EGTA and 1 mM phenylmethylsulfonyl fluoride (PMSF). The cell suspension was homogenized in a Dounce homogenizer and the mixture was centrifuged at 1000 g for 10 min at 4°C. The pellet was saved as nuclear fraction and the supernatant was further centrifuged at 100 000 g for 60 min at 4°C. The supernatant and pellet were saved as cytosolic and membrane fraction, respectively.
The cytoplasmic, nuclear and DNA pellet fractions of cells were prepared according to the described method. 24 The cells of 2 × 10 7 were pelleted down and added by 225 l of a buffer containing 10 mM Tris-HCl, pH 8.1, 140 mM NaCl, 1.5 mM MgCl 2 , 0.5% (vol/vol) NP-40 and 1.2 mM PMSF. The cell suspension was gently rotated for 5 min at 4°C and centrifuged at 800 g for 5 min. The supernatant was saved as cytoplasmic fraction and the pellet was suspended in 300 l of a buffer containing 20 mM Hepes-KOH, pH 7.6, 500 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.1 mM EGTA, 1.2 mM PMSF and 20% (vol/vol) glycerol. The mixture was rotated for 60 min at 4°C and centrifuged at 23 000 g for 15 min. The supernatant and pellet were saved as nuclear and DNA pellet fractions, respectively. The DNA pellet fraction was dissolved in a urea-TritonX-100 buffer.
Immunoblot analysis
Protein extracts obtained from an equal number of cells (5 × 10 5 ) were electrophoresed on SDS-polyacrylamide gels and blotted to the filter. All the procedures necessary for immunoblot analysis were as described previously. 25 It should be specified that the primary antibodies used were the anti-PEBP2␤/CBF␤ peptide antiserum 25 and the anti-AML1 peptide antiserum. The latter antiserum was raised in rabbits using as the peptide antigen the carboxy-terminal, 15 amino acid residues of murine AML1b/PEBP2␣B1 protein. The anti-PEBP2␤/CBF␤ chick serum and the anti-AML1 rabbit serum were used at 500-fold dilution. In a preabsorption experiment, 1 ml of 500-fold-diluted antiserum was incubated with 10 g of the antigen peptide on ice for 60 min prior to use in immunodetection.
Double immunofluorescent staining
The DNA pellet fraction of cells was prepared as above, suspended in phosphate buffered saline (PBS) and cytocentrifuged on to glass slides. The material was air-dried, fixed with 4% (wt/vol) paraformaldehyde in PBS for 20 min and blocked with 10% (wt/vol) skim milk in PBS for 30 min.
Anti-peptide specific antibodies were purified by passing 1 ml of 10-fold-diluted antiserum through an affinity column consisting of 3 mg of the peptide linked to a 1 ml bed volume of cyanogen bromide-activated Sepharose 4B (Pharmacia, Little Chalfont, UK). The anti-PEBP2␤/CBF␤ antibody was eluted from the column by a low pH buffer and was immediately neutralized, whereas the anti-AML1 antibody was eluted by 3 M sodium thiocyanate and was dialyzed against PBS.
The primary antibody used for double immunofluorescent staining was a mixture of affinity purified anti-PEBP2␤/CBF␤ and anti-AML1. The secondary antibody was a mixture of 100-fold-diluted FITC-conjugated goat IgG against chick IgY and RITC-conjugated goat IgG against rabbit IgG (Cappel, Aurora, Ohio, USA). Finally, the material was stained with 1 g/ml 4,6-diamidino-2-phenylindole dihydrochloride (DAPI). The sample was viewed through a confocal laser scanning microscope.
The AGM culture
Targeting of the AML1 gene was described previously. 22 The aorta-gonad-mesonephros (AGM) region was excised from wild-type and AML1 (−/−) mouse embryos at 11.5 days postcoitus and subjected to the tissue culture according to the published method. 26 After 5 days of culture, protein was extracted from the culture by the urea-Triton method. 23 
Results
inv(16) leukemic cells
We first checked for the expression of the chimeric PEBP2␤/CBF␤-MYH11 transcript in leukemic cells by RT-PCR analysis ( Figure 1 ). The sense and antisense primers used for amplification contained sequences found in the PEBP2␤/CBF␤ and MYH11 portions of the chimeric transcript. Amplified products were detected in the ME-1 cell line and inv(16)-carrying leukemic cells, but not in the Kasumi-1 cell line. The detected chimeric transcripts are judged to belong to the A type according to the published classification of various types of fusion transcripts. [1] [2] [3] This was based on restriction enzyme (AvaII) digestion of amplified products (data not shown). Transcripts of the hypoxanthine phosphoribosyl transferase gene were detected in all three RNA samples.
Distribution of PEBP2␤/CBF␤-SMMHC and Runt in subcellular fractions
We next examined the subcellular localization of the PEBP2␤/CBF␤-SMMHC chimeric protein by fractionating cells into cytosolic (C), membrane (M) and nuclear (N) fractions (Figure 2 ). Protein extracts from each fraction were processed for immunoblot analysis using the anti-peptide antibody directed against the amino-terminal region of PEBP2␤/CBF␤. 25 As can be seen in Figure 2a , the PEBP2␤/CBF␤-SMMHC protein of 70 kDa was readily detected in the nuclear and membrane fractions of the ME-1 cell line, but not in the cytosolic fraction. The PEBP2␤/CBF␤-SMMHC bands were abolished by including an excess amount of antigen peptide to the reaction, confirming the specificity of the immunoblot assay. We RT-PCR analysis of the PEBP2␤/CBF␤-MYH11 chimeric transcript in leukemic cell lines and leukemic cells. RNAs were prepared from the ME-1 and Kasumi-1 cell lines and also from fresh leukemic cells carrying inv(16)(p13q22) and were processed for RT-PCR analysis. The extreme left lane shows the DNA molecular weight marker.
obtained a similar result with the clinical isolate of leukemic cells carrying the inversion 16 ( Figure 2c ). The distribution of PEBP2␤/CBF␤ protein, on the other hand, was distinct from that of PEBP2␤/CBF␤-SMMHC (Figure 2b) . The PEBP2␤/CBF␤ protein was detected mainly in the nuclear and cytosolic fractions of both the ME-1 and Kasumi-1 cell lines. In the case of Kasumi-1, the membrane fraction also contained a small amount of PEBP2␤/CBF␤.
The detection of PEBP2␤/CBF␤-SMMHC protein in the nuclear fraction led us to examine the subcellular localization of its partner proteins. The protein extracts were processed for immunoblot analysis as described above except that the anti-AML1 peptide antiserum was used (Figure 3) . Interestingly, almost all of the Runt protein homologs were detected only in the nuclear subfraction of both ME-1 and Kasumi-1 cell lines (lanes 3 and 6) . The specificity of band detection was confirmed by including an excess amount of antigen peptide to the immunoblot assay (lanes 7 and 8). In fresh leukemic cells carrying inversion 16, the nuclei were again the major site for the localization of the Runt protein homologs (lane 11). Thus, in a manner somewhat distinct from that of PEBP2␤/CBF␤-SMMHC and PEBP2␤/CBF␤, the partner protein, Runt, was detected only in the nuclear fractions of the three leukemic cells examined. The AML1-MTG/ETO chimeric protein generated by t(8;21)(q22;q22) in the Kasumi-1 cell line was not detected by the antiserum used, since the peptide sequence chosen as the antigen is missing in the chimera.
The AML1 protein, one of the Runt protein homologs, is reported to be retained in the DNA pellet or nuclear matrix
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Figure 2
Immunoblot analysis of the PEBP2␤/CBF␤-SMMHC polypeptide in subcellular fractions of the leukemic cell lines and leukemic cells. The ME-1 and Kasumi-1 cell lines, as well as fresh leukemic cells carrying inv(16)(p13q22) were fractionated into cytosolic (C), membrane (M) and nuclear (N) fractions. Protein extracts were electrophoresed on SDS-8% (wt/vol) (panels a and c) or 12% (wt/vol) (panel b) polyacrylamide gels. Immunoblot analysis was performed using the anti-PEBP2␤/CBF␤ peptide antiserum as the primary antibody. Immunoreaction in the presence of an excess amount of antigen peptide was carried out in parallel (lanes 7 to 12 in panels a and b, lanes 4 to 6 in panel c). The numbers alongside the filters indicate the molecular weight in kilodaltons.
fractions of cells. 24, 27 The DNA pellet fraction represents the material remaining after extracting the nuclei with a high concentration of salt. The above-mentioned observations were obtained using the AML1-cDNA transfected cells. Whether this is also applicable to the Runt protein homologs present in the leukemic cells and whether the PEBP2␤/CBF␤-SMMHC protein can be retained as well in the same DNA pellet fraction would be an interesting point to be examined. The ME-1 cells were fractionated into cytoplasmic (C), nuclear (N) and DNA pellet (P) fractions (Figure 4) . A fair amount of both the PEBP2␤/CBF␤-SMMHC and Runt protein homologs were indeed detected in the DNA pellet fraction by immunoblot analysis (lane 3). Again, the specificity of band detection was confirmed by preabsorption of the antiserum with the antigen peptide (lane 6).
It must be noted that detection of PEBP2␤/CBF␤-SMMHC and Runt protein homologs in the cytoplasmic fraction (lane 1) appeared somewhat different from the results of cytosolic fraction described above (see Figure 2a , lane 1 and Figure 3 , lane 1). This is probably due to the different composition of buffers used to prepare respective fraction (see Materials and methods and note the presence or absence of detergent and salt concentration). Another notable feature was that all the PEBP2␤/CBF␤ was extracted into the cytoplasmic and nuclear fractions and was excluded from the DNA pellet fraction (Figure 4b ). The result indicates the different solubility between PEBP2␤/CBF␤ and its chimeric polypeptide.
Figure 3
Immunoblot analysis of Runt homologous polypeptides in subcellular fractions of the leukemic cell lines and fresh leukemic cells. Subcellular fractionation and immunoblot analysis were performed as described in Figure 2 , except that the anti-AML1 peptide antiserum was used as the primary antibody. In lanes 7 and 8, protein extracts from the nuclear fractions of ME-1 (lane 7) and Kasumi-1 cells (lane 8) were incubated with an excess amount of antigen peptide. The concentration of the polyacrylamide gel was 8% (wt/vol). The numbers alongside the filters indicate the molecular weight in kilodaltons.
Figure 4
Immunoblot analysis of the PEBP2␤/CBF␤-SMMHC, PEBP2␤/CBF␤ and Runt homologous polypeptides in subcellular fractions of the ME-1 cell line. The ME-1 cells were fractionated into cytoplasmic (C), nuclear (N) and DNA pellet (P) fractions. Protein extracts were electrophoresed on SDS-8% (wt/vol) (panels a and c) or 12% (wt/vol) (panel b) polyacrylamide gels. Immunoblot analysis was performed using the anti-PEBP2␤/CBF␤ peptide antiserum (panels a and b) or the anti-AML1 peptide antiserum (panel c) as the primary antibody. Immunoreaction in the presence of an excess amount of antigen peptide was carried out in parallel (lanes 4 to 6). The numbers alongside the filters indicate the molecular weight in kilodaltons.
Double staining of PEBP2␤/CBF␤-SMMHC and Runt
Recruitment of both PEBP2␤/CBF␤-SMMHC and Runt in the same DNA pellet fraction as shown above then led us to study their spatial distribution in the fraction. We examined this by double immunofluorescent staining of DNA pellet fraction prepared from the ME-1 cells ( Figure 5 ). Both the FITC fluorescence representing the PEBP2␤/CBF␤-SMMHC (Figure 5a ) and the RITC fluorescence representing the Runt protein homologs (Figure 5b ) showed several to multiple, granular staining on the DNA pellet fraction of cells. This fluorescence is judged to be due to specific immunoreactions based on a preabsorption experiment (data not shown). Interestingly, when panels a and b were overlayed, yellow fluorescence was generated at two discrete and proximate spots (panel c). The result indicates that some PEBP2␤/CBF␤-SMMHC and Runt protein homologs are actually colocalized in the DNA pellet fraction. DAPI staining in Figure 5d shows the contour of remaining DNA on which most of the fluorescence was detected. In addition, the essentially similar result was obtained by immunofluorescently staining the inv(16) leukemic cells from the patient (data not shown).
We did not perform double immunofluorescent staining of unfractionated ME-1 cells. If the cells were processed for immunofluorescent staining without cell fractionation, the fluorescence, if any, delivered by the anti-PEBP2␤/CBF␤ peptide antibody could not be assigned to either PEBP2␤/CBF␤, PEBP2␤/CBF␤-SMMHC or both, since the antibody recognizes both polypeptides. In the DNA pellet subfraction of cells, however, the fluorescence delivered by this antibody is considered to be derived only from the chimeric molecule and not from the PEBP2␤/CBF␤ (see Figure 4, lane 3) .
Identification of AML1 among the Runt protein homologs
In immunoblot analysis using the anti-AML1 antiserum, we detected multiple bands with molecular masses of 60 kDa to 52 kDa. This is probably due to cross-reactivity of the antiserum with the products of mammalian runt family genes, since they all share the common VWRPY sequence at their extreme carboxy-terminal ends 10 and the antiserum was raised against the carboxy-terminal portion of AML1 protein.
We finally tried to identify the AML1 gene products among the Runt protein homologs by using the gene targeted murine embryos. The AGM region was dissected from the wild-type and AML1 (−/−) embryos and subjected to the tissue culture. Protein extracts from the culture were processed for immunoblot analysis using the anti-AML1 peptide antiserum ( Figure  6 ). Three discrete bands of 62, 58 and 56 kDa were detected in the wild-type culture (lane 3). The 58 and 56 kDa bands most likely represent the AML1-derived products, since they were absent in the AML1 (−/−) culture (lane 4) and the 56 kDa band comigrated with the AML1 protein purified from a bacterial lysate (lane 2). The 58 kDa band is likely a phosphorylated form of 56 kDa band. 28, 29 Therefore, the 58 and 56 kDa bands detected in the human leukemic cells (see Figure 4c , lane 3) most likely represent the AML1 gene products as well, if the difference in species (human vs murine) and cell types (leukemic cells vs the AGM region) do not affect the molecular masses greatly.
It must be noted that the 62 kDa band was detected in the wild-type, as well as the AML1 (−/−) AGM culture and that it comigrated with the PEBP2␣A protein purified from a bacterial lysate ( Figure 6, lanes 1, 3 and 4) . PEBP2␣A is another member of the mammalian runt gene family. All three bands mentioned above were abolished when the antiserum was preabsorbed with the antigen peptide (lanes 5 and 6).
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Discussion
In the present study, we observed that the nuclear fraction of leukemic cells carrying inversion 16 contained both the PEBP2␤/CBF␤-SMMHC protein and Runt protein homologs. Our observations are in sharp contrast to recent reports indicating that both the PEBP2␤/CBF␤-SMMHC and AML1 proteins are retained in the cytoplasm and excluded from the nucleus when they are expressed together. 17, 19 The exact reason for the above discrepancy is not known at present. However, it may be worth considering that different cells were used in both studies. As mentioned above, fibroblastic and T cell lines were used when cytoplasmic retention was observed. 17, 19 Furthermore, the possibility that these proteins may have been overexpressed by the expression plasmids used to transfect the cells should be taken into consideration when interpreting the data. We avoided these problems by analyzing the subcellular localizations of the endogenously expressed proteins in leukemic cells. Our results indicate that the so-called dominant interfering effect of PEBP2␤/CBF␤-SMMHC on PEBP2/CBF function must be re-examined in terms of their subcellular localization. In this sense, particularly intriguing is our present observation that the normal Runt protein homologs and their chimeric counterpart are Immunoblot analysis of the Runt protein homologs in the AGM culture. Protein extracts were prepared from the wild-type and AML1 (−/−) AGM cultures and processed for immunoblot analysis as described in Figure 3 . The anti-AML1 peptide antiserum was used as the primary antibody in lanes 1 to 4, whereas the antiserum was preabsorbed with an excess amount of antigen peptide in lanes 5 and 6. In lanes 1 and 2, the AML1 and PEBP2␣A proteins purified from bacterial lysates were loaded. The numbers alongside the filters indicate the molecular weight in kilodaltons.
colocalized at least partially in the DNA pellet fraction as revealed by double immunofluorescent staining.
The nuclear localization of PEBP2␤/CBF␤-SMMHC is supported by several other reports. For example, stable transformants of Ba/F3 (lymphoid) and 32Dc13 (myeloid) cell lines were reported to express PEBP2␤/CBF␤-SMMHC in the nucleus. 16, 30 Interestingly, endogenous PEBP2/CBF DNA binding activity is greatly reduced in these transformants. In addition, in neutrophils from mice which express PEBP2␤/CBF␤-MYH11 as a transgene, the chimeric protein was detected in the nucleus. 31 The presence of the chimeric protein in fresh leukemic cells taken from AML-M4Eo patients has been reported previously by immunoblot analysis of whole cell lysates. 32 As for the subcellular localization of PEBP2␤/CBF␤-SMMHC in leukemic cells, there has been only one previous report. 33 According to this report, the PEBP2␤/CBF␤-SMMHC protein was predominantly distributed in the nucleus, although a minor fraction was also detected in the cytoplasm. Although the cellular distribution of PEBP2␤/CBF␤-SMMHC described in this study is in apparent accord with the results of other reports listed in this section, our study is the first to demonstrate the simultaneous nuclear localization of Runt protein homologs.
Another new finding of the present study was the observed presence of a small amount of PEBP2␤/CBF␤-SMMHC in the membrane subfraction of leukemic cells. Since this membrane-located PEBP2␤/CBF␤-SMMHC is considered to be located away from the Runt protein homologs, it may exert a function distinct from that of the nuclear-located chimera. We previously reported that the transient expression of the PEBP2␤/CBF␤-SMMHC protein in the C2C12 myoblast cell line resulted in drastic morphological changes and the presence of protein in the cell membrane and nuclear subfractions. 23 We suggested the disorganization of the cytoplasmic stress fibers observed in the transfected C2C12 cells to be somehow related to the membrane localization of chimeric protein. The dual functions exerted by the membrane-and nuclear-located PEBP2␤/CBF␤-SMMHC protein that we proposed previously may be applicable to leukemic cells carrying inversion 16 and may provide a clue to unraveling the molecular mechanisms of myeloid leukemogenesis.
